402 related articles for article (PubMed ID: 31542509)
41. The C. elegans PRMT-3 possesses a type III protein arginine methyltransferase activity.
Takahashi Y; Daitoku H; Yokoyama A; Nakayama K; Kim JD; Fukamizu A
J Recept Signal Transduct Res; 2011 Apr; 31(2):168-72. PubMed ID: 21385054
[TBL] [Abstract][Full Text] [Related]
42. Histone arginine methylation.
Di Lorenzo A; Bedford MT
FEBS Lett; 2011 Jul; 585(13):2024-31. PubMed ID: 21074527
[TBL] [Abstract][Full Text] [Related]
43. Introduction to the multi-author review on methylation in cellular physiology.
Shechter D
Cell Mol Life Sci; 2019 Aug; 76(15):2871-2872. PubMed ID: 31177294
[TBL] [Abstract][Full Text] [Related]
44. Arginine methyltransferases in normal and malignant hematopoiesis.
Greenblatt SM; Liu F; Nimer SD
Exp Hematol; 2016 Jun; 44(6):435-41. PubMed ID: 27026282
[TBL] [Abstract][Full Text] [Related]
45. Small molecule inhibitors that discriminate between protein arginine N-methyltransferases PRMT1 and CARM1.
Dowden J; Pike RA; Parry RV; Hong W; Muhsen UA; Ward SG
Org Biomol Chem; 2011 Oct; 9(22):7814-21. PubMed ID: 21952734
[TBL] [Abstract][Full Text] [Related]
46. Regulation of histone arginine methylation/demethylation by methylase and demethylase (Review).
Zhang J; Jing L; Li M; He L; Guo Z
Mol Med Rep; 2019 May; 19(5):3963-3971. PubMed ID: 30942418
[TBL] [Abstract][Full Text] [Related]
47. Combinations of histone post-translational modifications.
Taylor BC; Young NL
Biochem J; 2021 Feb; 478(3):511-532. PubMed ID: 33567070
[TBL] [Abstract][Full Text] [Related]
48. A patent review of arginine methyltransferase inhibitors (2010-2018).
Li X; Wang C; Jiang H; Luo C
Expert Opin Ther Pat; 2019 Feb; 29(2):97-114. PubMed ID: 30640571
[TBL] [Abstract][Full Text] [Related]
49. The story of protein arginine methylation: characterization, regulation, and function.
Peng C; Wong CC
Expert Rev Proteomics; 2017 Feb; 14(2):157-170. PubMed ID: 28043171
[TBL] [Abstract][Full Text] [Related]
50. Protein arginine methyltransferases: insights into the enzyme structure and mechanism at the atomic level.
Tewary SK; Zheng YG; Ho MC
Cell Mol Life Sci; 2019 Aug; 76(15):2917-2932. PubMed ID: 31123777
[TBL] [Abstract][Full Text] [Related]
51. Functional Study of
Lorenzon L; Quilles JC; Campagnaro GD; Azevedo Orsine L; Almeida L; Veras F; Miserani Magalhães RD; Alcoforado Diniz J; Rodrigues Ferreira T; Kaysel Cruz A
ACS Infect Dis; 2022 Mar; 8(3):516-532. PubMed ID: 35226477
[TBL] [Abstract][Full Text] [Related]
52. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation.
Wang J; Chen L; Sinha SH; Liang Z; Chai H; Muniyan S; Chou YW; Yang C; Yan L; Feng Y; Li KK; Lin MF; Jiang H; Zheng YG; Luo C
J Med Chem; 2012 Sep; 55(18):7978-87. PubMed ID: 22928876
[TBL] [Abstract][Full Text] [Related]
53. The protein arginine methyltransferase family: an update about function, new perspectives and the physiological role in humans.
Wolf SS
Cell Mol Life Sci; 2009 Jul; 66(13):2109-21. PubMed ID: 19300908
[TBL] [Abstract][Full Text] [Related]
54. Protein Arginine Methyltransferase Product Specificity Is Mediated by Distinct Active-site Architectures.
Jain K; Warmack RA; Debler EW; Hadjikyriacou A; Stavropoulos P; Clarke SG
J Biol Chem; 2016 Aug; 291(35):18299-308. PubMed ID: 27387499
[TBL] [Abstract][Full Text] [Related]
55. Practical Guidelines for High-Resolution Epigenomic Profiling of Nucleosomal Histones in Postmortem Human Brain Tissue.
Kundakovic M; Jiang Y; Kavanagh DH; Dincer A; Brown L; Pothula V; Zharovsky E; Park R; Jacobov R; Magro I; Kassim B; Wiseman J; Dang K; Sieberts SK; Roussos P; Fromer M; Harris B; Lipska BK; Peters MA; Sklar P; Akbarian S
Biol Psychiatry; 2017 Jan; 81(2):162-170. PubMed ID: 27113501
[TBL] [Abstract][Full Text] [Related]
56. Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions.
Tong C; Chang X; Qu F; Bian J; Wang J; Li Z; Xu X
Eur J Med Chem; 2024 Mar; 267():116212. PubMed ID: 38359536
[TBL] [Abstract][Full Text] [Related]
57. Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition.
Shishkova E; Zeng H; Liu F; Kwiecien NW; Hebert AS; Coon JJ; Xu W
Nat Commun; 2017 May; 8():15571. PubMed ID: 28537268
[TBL] [Abstract][Full Text] [Related]
58. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
59. Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases.
Lakowski TM; 't Hart P; Ahern CA; Martin NI; Frankel A
ACS Chem Biol; 2010 Nov; 5(11):1053-63. PubMed ID: 20701328
[TBL] [Abstract][Full Text] [Related]
60. Readers of histone methylarginine marks.
Gayatri S; Bedford MT
Biochim Biophys Acta; 2014 Aug; 1839(8):702-10. PubMed ID: 24583552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
